Literature DB >> 240655

Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species.

C L Litterst, E G Mimnaugh, R L Reagan, T E Gram.   

Abstract

Comparative studies of in vitro drug metabolism by hepatic and extrahepatic tissues have been complicated by the use of a single experimental tissue, few animal species, and variable experimental conditions. In an attempt to minimize these complications, liver, lung and kidney from rat, mouse, rabbit, hamster, and guinea pig were assayed for standard microsomal and soluble fraction enzymes involved in drug biotransformation. For all species, liver was the most active organ. Kidney and lung activities were usually 15%-40% of those found in liver, with kidney slightly more active than lung. No single species demonstrated total superiority in its drug-metabolizing ability, although hamster showed a large number of instances of greatest activity. The rat was a surprisingly poor representative of drug-metabolizing ability; it was superior to the other four species in less than 25% of the instances studied. All species appeared to N-demethylate aminopyrine equally except for high pulmonary and nearly absent renal activities in rabbit and high hepatic activity in hamster. Rat had the lowest level of cytochrome P-450 and low activity of NADPH-cytochrome c reductase. UDP-glucuronyltransferase activity toward the acceptors p-nitrophenol and o-aminophenol was higher in hamster and rabbit than other species. Guinea pig appeared to have the most active soluble fraction enzymes. Mouse lung and kidney had glutathione S-aryltransferase activities 10-fold greater than any other species and comparable to liver activity from rabbit and hamster.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 240655

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  26 in total

Review 1.  Interaction of chemical carcinogens and drug-metabolizing enzymes in primary cultures of hepatic cells from the rat.

Authors:  G Michalopoulos; G Sattler; C Sattler; H C Pitot
Journal:  Am J Pathol       Date:  1976-12       Impact factor: 4.307

2.  Irreversible protein binding of 14C-imipramine in rats in vivo.

Authors:  H Kappus
Journal:  Arch Toxicol       Date:  1976-12-23       Impact factor: 5.153

3.  Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Jee H Shin; Ka Y Choi; Yu C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 4.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  Biological N-oxidation of adenine and 9-alkyl derivatives.

Authors:  S P Lam; F Devinsky; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Oct-Dec       Impact factor: 2.441

6.  Nutrient plasma levels achieved during treatment that reduces noise-induced hearing loss.

Authors:  Colleen G Le Prell; David F Dolan; David C Bennett; Peter A Boxer
Journal:  Transl Res       Date:  2011-03-09       Impact factor: 7.012

7.  Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.

Authors:  Y Igari; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

8.  Differences in the effects of model inducers of cytochrome P450 on the biotransformation of scoparone in rat and hamster liver.

Authors:  W C Mennes; N B Luijckx; H M Wortelboer; J Noordhoek; B J Blaauboer
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

9.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

10.  Tissue and sex-dependent differences in CYP2A activities in hamsters.

Authors:  P Pelkonen; M Lang; M Pasanen
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.